We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Biomea Fusion, Inc. (NASDAQ:BMEA) stands against the other diabetes ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

D. Boral Capital lowered the firm’s price target on Biomea Fusion (BMEA) to $16 from $128 and keeps a Buy rating on the shares. The company ...

D. Boral Capital reiterated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA – Free Report) in a report issued on ...

Biomea Fusion, Inc. announced positive results from preclinical experiments showing that its investigational drug icovamenib enhances beta cell function and improves the responsiveness of human ...

Biomea Fusion will discuss COVALENT-111 Phase II trial results for icovamenib in type 2 diabetes on December 17, 2024. Biomea Fusion, Inc. announced that it will host a conference call and webcast ...

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined ...

REDWOOD CITY, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical ...

Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions.

Biomea Fusion, Inc. (NASDAQ:BMEA), a biotechnology company focused on developing treatments for genetically defined cancers and diabetes, finds itself at a critical juncture as it navigates clinical ...